(Q54238337)

26 May 2018

title

Immunological factors influencing clinical outcome in lung cancer patients after telomerase peptide vaccination. (English)

1 reference

26 May 2018

1 reference

2

Gustav Gaudernack

1 reference

26 May 2018

Gaute Lund Hansen

1

1 reference

26 May 2018

Paal Fredrik Brunsvig

series ordinal

3

1 reference

26 May 2018

Milada Cvancarova

series ordinal

4

1 reference

26 May 2018

Jon Amund Kyte

series ordinal

5

1 reference

26 May 2018

publication date

26 October 2015

1 reference

26 May 2018

Cancer Immunology, Immunotherapy

published in

1 reference

26 May 2018

volume

64

1 reference

26 May 2018

issue

12

1 reference

26 May 2018

page(s)

1609-1621

1 reference

26 May 2018

https://scigraph.springernature.com/pub.10.1007/s00262-015-1766-5

exact match

0 references

cites work

Pembrolizumab for the treatment of non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1766-5

Therapeutic vaccines for cancer: an overview of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1766-5

Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: A dose escalating phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1766-5

Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1766-5

Telomerase peptide vaccination combined with temozolomide: a clinical trial in stage IV melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1766-5

A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1766-5

Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1766-5

Cloning yeast telomeres on linear plasmid vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1766-5

Identification of a specific telomere terminal transferase activity in Tetrahymena extracts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1766-5

Specific Association of Human Telomerase Activity with Immortal Cells and Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1766-5

Telomeres and telomerase in lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1766-5

Immunization of patients with the hTERT:540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1766-5

The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1766-5

Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1766-5

Unconventional cytokine profiles and development of T cell memory in long-term survivors after cancer vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1766-5

Tumor antigen-specific T helper cells in cancer immunity and immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1766-5

Myeloid-derived suppressor cells: linking inflammation and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1766-5

Myeloid-derived suppressor cells as regulators of the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1766-5

Functional characterization of human Cd33+ and Cd11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1766-5

Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1766-5

A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1766-5

Phenotypic and functional features of human Th17 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1766-5

T helper 17 cells promote cytotoxic T cell activation in tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1766-5

T cell responses in melanoma patients after vaccination with tumor-mRNA transfected dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1766-5

Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1766-5

Regulatory T cells, tumour immunity and immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1766-5

T regulatory cells in cancer: recent advances and therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1766-5

Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1766-5

Widespread CD4+ T-cell reactivity to novel hTERT epitopes following vaccination of cancer patients with a single hTERT peptide GV1001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1766-5

Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1766-5

Increased CD14(+)HLA-DR (-/low) myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1766-5

Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1766-5

Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1766-5

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1766-5

Depleting tumor-specific Tregs at a single site eradicates disseminated tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1766-5

Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1766-5

Polyfunctional T cell responses are a hallmark of HIV-2 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1766-5

Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1766-5

Increased Level of both CD4+FOXP3+ Regulatory T Cells and CD14+HLA-DR−/low Myeloid-Derived Suppressor Cells and Decreased Level of Dendritic Cells in Patients with Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1766-5

10.1007/S00262-015-1766-5

21 January 2018

Identifiers

DOI

1 reference

26 May 2018

PubMed ID

26498005

1 reference

26 May 2018